世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

甲状腺疾患治療市場:疾患タイプ別(甲状腺機能亢進症、甲状腺機能低下症)、薬剤タイプ別(レボチロキシン、リオチロニン、プロピルチオウラシル、イミダゾール系化合物、その他)、投与経路別(経口、点滴、その他)、流通・販売チャネル別(卸売業者・販売店、小売業者、通信販売薬局、その他)-世界全体および2027年までの予測


Thyroid Gland Disorder Treatment Market by Disease Type (Hyperthyroidism and Hypothyroidism), Drug Type (Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compound, and Others), Route of Administration (Oral, Intravenous, and Others), and Distribution/Sales Channel (Wholesaler/Distributor, Retailer, Mail-order Pharmacy, and Others) - Global and Forecast up to 2027

甲状腺疾患治療市場は、甲状腺疾患の管理および治療に使用される製品および治療法の市場を指す。甲状腺は、首の前に位置する小さな蝶の形をした腺で、いくつかの身体機能を調節するために必要なホルモンを産生す... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IHR Insights
アイエイチアールインサイト
2023年7月7日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
223 英語

 

サマリー

甲状腺疾患治療市場は、甲状腺疾患の管理および治療に使用される製品および治療法の市場を指す。甲状腺は、首の前に位置する小さな蝶の形をした腺で、いくつかの身体機能を調節するために必要なホルモンを産生する。甲状腺疾患は、甲状腺からのホルモン分泌が多すぎる場合(甲状腺機能亢進症)、または少なすぎる場合(甲状腺機能低下症)に起こります。甲状腺疾患の有病率の増加:甲状腺機能低下症、甲状腺機能亢進症、甲状腺結節を含む甲状腺疾患は、世界的に流行しつつある。座りがちなライフスタイル、ストレス、環境汚染、食生活のアンバランスなどの要因が、甲状腺疾患の罹患率上昇に寄与している。その結果、診断検査、薬剤、治療オプションに対する需要が高まり、市場の成長を牽引している。一方、患者のアドヒアランス低下を引き起こす悪影響や厳しい政府規制などの要因は、甲状腺障害治療市場の成長を妨げる可能性が高い。甲状腺疾患治療市場は、2027年までに年平均成長率4.8%で成長するとみられる。
甲状腺疾患治療市場:疾患タイプ別
- 甲状腺機能低下症
- 甲状腺機能亢進症
甲状腺疾患治療薬市場:薬剤タイプ別
- レボサイロキシン
- リオチロニン
- プロピルチオウラシル
- イミダゾール系化合物
甲状腺疾患治療薬市場:投与経路別
- 経口
- 静脈内投与
甲状腺疾患治療薬市場:流通チャネル別
- 卸売業者/販売業者 小売業者 通信販売薬局 その他
- 小売
- 通販薬局
甲状腺疾患治療薬市場:地域別
- 北米
- 欧州
- アジア太平洋
- その他の地域
以下は、甲状腺疾患市場の主要な側面の概要である:
甲状腺機能低下症の治療:甲状腺機能低下症は、甲状腺が十分な甲状腺ホルモンを産生しない場合に起こる。甲状腺機能低下症の主な治療は、合成甲状腺ホルモン薬、典型的にはレボチロキシンによるホルモン補充療法である。レボチロキシンは経口投与され、体内のホルモンレベルを回復させるのに役立ちます。
甲状腺機能亢進症の治療甲状腺機能亢進症は、甲状腺が甲状腺ホルモンを過剰に産生することで起こります。甲状腺機能亢進症の治療法には、薬物療法、放射性ヨード療法、手術があります。メチマゾールやプロピルチオウラシルなどの抗甲状腺薬は、甲状腺ホルモンの産生を抑えるのに役立ちます。放射性ヨード療法では、放射性ヨードを投与し、活動しすぎの甲状腺細胞を破壊または縮小させます。少数のケースでは、甲状腺の全部または一部の外科的切除(甲状腺切除術)が必要になることもあります。
診断検査:甲状腺機能を評価し、甲状腺障害を発見するために、さまざまな診断検査が行われます。甲状腺刺激ホルモン(TSH)、遊離サイロキシン(T4)、トリヨードサイロニン(T3)などの血液検査は、ホルモンレベルを評価するためによく行われます。甲状腺を可視化し、異常を検出するために、超音波検査や核医学検査のような画像診断技術が使用されることもある。
市場動向:甲状腺疾患市場にはいくつかのトレンドがある。スクリーニングプログラムや認知度の向上を通じて、甲状腺疾患の早期発見・診断に注目が集まっている。診断技術の進歩により、甲状腺機能検査の精度と効率が向上している。さらに、甲状腺機能亢進症に対する新規薬剤や、特定の遺伝性甲状腺疾患に対する潜在的な遺伝子治療など、特定の甲状腺疾患に対する標的療法を開発するための研究が進行中である。
甲状腺がんの治療甲状腺がんは比較的まれではあるが、甲状腺疾患市場のもう一つの側面である。甲状腺癌の治療には通常、癌化した甲状腺組織を除去する手術と、残存する甲状腺細胞を破壊するための放射性ヨード療法が含まれる。場合によっては、進行または再発甲状腺がんの治療に外部照射療法や標的療法が用いられることもある。
甲状腺疾患市場の主要大手企業は、Abbott Laboratories、AbbVie Inc、Allergan Plc、GlaxoSmithKline plc、Lannett Company, Inc、Merck & Co.Inc、Mylan N.V、Novartis AG、Pfizer Inc、RLC LABS, Incである。
甲状腺疾患の治療アプローチは、特定の診断、症状の重症度、個々の患者の特徴、および医療専門家の指導によって異なることに注意することが重要である。治療を最適化し、甲状腺疾患を効果的に管理するためには、医療従事者による定期的なモニタリングとフォローアップが極めて重要である。
- 本レポートには、すべての主要な地理的地域の独占的分析が含まれており、これらの地域における潜在的な機会を決定しています。
- 予測期間における甲状腺障害治療市場の成長を生み出している属性に関する詳細情報。
- 甲状腺障害治療市場シェアと親市場への貢献の正確な推定は、レポートで提供されます。
- また、主要な競合企業のプロフィールとそのダイナミックな戦略も調査対象としています。


ページTOPに戻る


目次

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Disease Type: Market Size & Analysis
5.1. Overview
5.2. Hypothyroidism
5.3. Hyperthyroidism
6. Drug Type: Market Size & Analysis
6.1. Overview
6.2. Levothyroxine
6.3. Liothyronine
6.4. Propylthiouracil
6.5. Imidazole-based compounds
7. Route Of Administration: Market Size & Analysis
7.1. Overview
7.2. Oral
7.3. Intravenous route
8. Distribution Channel: Market Size & Analysis
8.1. Overview
8.2. Wholesaler/Distributor Retailer Mail-order Pharmacy Others
8.3. Retailer
8.4. Mail-Order Pharmacy
9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. Vendor Profiles
11.1. Abbott Laboratories
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. AbbVie Inc
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Allergan Plc
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. GlaxoSmithKline plc
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Lannett Company, Inc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Merck & Co. Inc
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Mylan N.V
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Novartis AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Pfizer Inc
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. RLC LABS, Inc
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. Analyst Opinion
13. Annexure
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations

ページTOPに戻る



図表リスト

TABLE 1. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPOTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPERTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LEVOTHYROXINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LIOTHYRONINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR PROPYLTHIOURACIL, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR IMIDAZOLE-BASED COMPOUNDS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR ORAL, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR INTRAVENOUS ROUTE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR WHOLESALER/DISTRIBUTOR RETAILER MAIL-ORDER PHARMACY OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR RETAILER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR MAIL-ORDER PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 17. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 18. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 19. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 20. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 21. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 22. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 23. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 24. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 25. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 26. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 27. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 29. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 30. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 31. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 32. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 33. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 34. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 35. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 36. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 37. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 38. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 39. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 40. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 42. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 43. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 44. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 46. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 47. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 48. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 49. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 50. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 51. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 52. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 54. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 55. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 56. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 59. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 60. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 61. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 62. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 63. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 64. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 65. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 67. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 68. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 69. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 70. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 71. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 72. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 73. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 74. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 75. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 76. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 77. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 78. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 79. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 80. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 81. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 82. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC: FINANCIALS
TABLE 87. ABBVIE INC: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 89. ALLERGAN PLC: FINANCIALS
TABLE 90. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 91. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 92. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 94. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 95. LANNETT COMPANY, INC: FINANCIALS
TABLE 96. LANNETT COMPANY, INC: PRODUCTS & SERVICES
TABLE 97. LANNETT COMPANY, INC: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO. INC: FINANCIALS
TABLE 99. MERCK & CO. INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO. INC: RECENT DEVELOPMENTS
TABLE 101. MYLAN N.V: FINANCIALS
TABLE 102. MYLAN N.V: PRODUCTS & SERVICES
TABLE 103. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 104. NOVARTIS AG: FINANCIALS
TABLE 105. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 106. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 107. PFIZER INC: FINANCIALS
TABLE 108. PFIZER INC: PRODUCTS & SERVICES
TABLE 109. PFIZER INC: RECENT DEVELOPMENTS
TABLE 110. RLC LABS, INC: FINANCIALS
TABLE 111. RLC LABS, INC: PRODUCTS & SERVICES
TABLE 112. RLC LABS, INC: RECENT DEVELOPMENTS

 

ページTOPに戻る


 

Summary

The thyroid gland disorder treatment market refers to the market for products and therapies used in the management and treatment of thyroid gland disorders. The thyroid gland refers to a small butterfly-shaped gland situated in the front of the neck which produces hormones required for regulating several bodily functions. Thyroid disorders can occur when the thyroid gland produces too much hormone (hyperthyroidism) or too little hormone (hypothyroidism. Increasing Prevalence of Thyroid Disorders: Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, are becoming more prevalent globally. Factors such as sedentary lifestyles, stress, environmental pollution, and dietary imbalances contribute to the rising incidence of thyroid gland disorders. As a result, there is a growing demand for diagnostic tests, medications, and treatment options, driving the market's growth. On the other hand, the factors such as negative impacts which cause lesser patient adherence and strict government regulations are likely to hamper the thyroid gland disorder treatment market growth. Thyroid Gland Disorder Treatment Market is likely to grow at a rate of 4.8% CAGR by 2027.
Thyroid Gland Disorder Treatment Market by Disease Type
• Hypothyroidism
• Hyperthyroidism
Thyroid Gland Disorder Treatment Market by Drug Type
• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based compounds
Thyroid Gland Disorder Treatment Market by Route Of Administration
• Oral
• Intravenous route
Thyroid Gland Disorder Treatment Market by Distribution Channel
• Wholesaler/Distributor Retailer Mail-order Pharmacy Others
• Retailer
• Mail-Order Pharmacy
Thyroid Gland Disorder Treatment Market by Geography
• North America
• Europe
• Asia Pacific
• Rest of the World
Here is an overview of the key aspects of the thyroid gland disorder market:
Hypothyroidism Treatment: Hypothyroidism occurs when the thyroid gland doesn't produce enough thyroid hormone. The main treatment for hypothyroidism is hormone replacement therapy with synthetic thyroid hormone medication, typically levothyroxine. Levothyroxine is taken orally and helps restore the hormone levels in the body.
Hyperthyroidism Treatment: Hyperthyroidism occurs when the thyroid gland produces an excess of thyroid hormone. Treatment options for hyperthyroidism are medications, radioactive iodine therapy and surgery. Antithyroid medications, such as methimazole and propylthiouracil, can help reduce the production of thyroid hormone. Radioactive iodine therapy involves the administration of radioactive iodine, which destroys or shrinks the overactive thyroid cells. In few cases, surgical removal of all or part of the thyroid gland (thyroidectomy) may be required.
Diagnostic Tests: Various diagnostic tests are used to evaluate thyroid function and detect thyroid disorders. Blood tests, such as thyroid-stimulating hormone (TSH), free thyroxine (T4), and triiodothyronine (T3) tests, are commonly performed to assess hormone levels. Imaging techniques like ultrasound and nuclear medicine scans may be used to visualize the thyroid gland and detect abnormalities.
Market Trends: The thyroid gland disorder market is experiencing several trends. There is a growing focus on early detection and diagnosis of thyroid disorders through screening programs and increased awareness. Advances in diagnostic technologies are improving the accuracy and efficiency of thyroid function testing. Additionally, research is ongoing to develop targeted therapies for specific thyroid disorders, such as novel medications for hyperthyroidism and potential gene therapies for certain genetic thyroid disorders.
Thyroid Cancer Treatment: Thyroid cancer, though relatively rare, is another aspect of the thyroid gland disorder market. Treatment for thyroid cancer typically involves surgery to remove the cancerous thyroid tissue, followed by radioactive iodine therapy to destroy any remaining thyroid cells. In some cases, external beam radiation therapy and targeted therapies may be used to treat advanced or recurrent thyroid cancer.
The major leading companies of the thyroid gland disorder market are Abbott Laboratories, AbbVie Inc, Allergan Plc, GlaxoSmithKline plc, Lannett Company, Inc, Merck & Co. Inc, Mylan N.V, Novartis AG, Pfizer Inc, and RLC LABS, Inc
It's important to note that the treatment approach for thyroid gland disorders depends on the specific diagnosis, severity of symptoms, individual patient characteristics, and the guidance of healthcare professionals. Regular monitoring and follow-up with healthcare providers are crucial for optimizing treatment and managing thyroid gland disorders effectively.
• An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
• Detailed information about the attributes which are generating growth in the thyroid gland disorder treatment market in the forecast period.
• An exact estimation of the thyroid gland disorder treatment market share and its contribution to the parent market is provided in the report.
• Further profiles of key competitors and their dynamic strategies are also covered in the study.



ページTOPに戻る


Table of Contents

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Disease Type: Market Size & Analysis
5.1. Overview
5.2. Hypothyroidism
5.3. Hyperthyroidism
6. Drug Type: Market Size & Analysis
6.1. Overview
6.2. Levothyroxine
6.3. Liothyronine
6.4. Propylthiouracil
6.5. Imidazole-based compounds
7. Route Of Administration: Market Size & Analysis
7.1. Overview
7.2. Oral
7.3. Intravenous route
8. Distribution Channel: Market Size & Analysis
8.1. Overview
8.2. Wholesaler/Distributor Retailer Mail-order Pharmacy Others
8.3. Retailer
8.4. Mail-Order Pharmacy
9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
10.2.2. Product Launches and execution
11. Vendor Profiles
11.1. Abbott Laboratories
11.1.1. Overview
11.1.2. Financial Overview
11.1.3. Product Offerings
11.1.4. Developments
11.1.5. Business Strategy
11.2. AbbVie Inc
11.2.1. Overview
11.2.2. Financial Overview
11.2.3. Product Offerings
11.2.4. Developments
11.2.5. Business Strategy
11.3. Allergan Plc
11.3.1. Overview
11.3.2. Financial Overview
11.3.3. Product Offerings
11.3.4. Developments
11.3.5. Business Strategy
11.4. GlaxoSmithKline plc
11.4.1. Overview
11.4.2. Financial Overview
11.4.3. Product Offerings
11.4.4. Developments
11.4.5. Business Strategy
11.5. Lannett Company, Inc
11.5.1. Overview
11.5.2. Financial Overview
11.5.3. Product Offerings
11.5.4. Developments
11.5.5. Business Strategy
11.6. Merck & Co. Inc
11.6.1. Overview
11.6.2. Financial Overview
11.6.3. Product Offerings
11.6.4. Developments
11.6.5. Business Strategy
11.7. Mylan N.V
11.7.1. Overview
11.7.2. Financial Overview
11.7.3. Product Offerings
11.7.4. Developments
11.7.5. Business Strategy
11.8. Novartis AG
11.8.1. Overview
11.8.2. Financial Overview
11.8.3. Product Offerings
11.8.4. Developments
11.8.5. Business Strategy
11.9. Pfizer Inc
11.9.1. Overview
11.9.2. Financial Overview
11.9.3. Product Offerings
11.9.4. Developments
11.9.5. Business Strategy
11.10. RLC LABS, Inc
11.10.1. Overview
11.10.2. Financial Overview
11.10.3. Product Offerings
11.10.4. Developments
11.10.5. Business Strategy
12. Analyst Opinion
13. Annexure
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations

ページTOPに戻る



List of Tables/Graphs

TABLE 1. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 2. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPOTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR HYPERTHYROIDISM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LEVOTHYROXINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR LIOTHYRONINE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR PROPYLTHIOURACIL, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR IMIDAZOLE-BASED COMPOUNDS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 10. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR ORAL, 2020-2026 (USD BILLION)
TABLE 11. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR INTRAVENOUS ROUTE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 13. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR WHOLESALER/DISTRIBUTOR RETAILER MAIL-ORDER PHARMACY OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 14. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR RETAILER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET VALUE FOR MAIL-ORDER PHARMACY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 17. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 18. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 19. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 20. NORTH AMERICA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 21. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 22. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 23. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 24. U.S THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 25. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 26. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 27. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 28. CANADA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 29. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 30. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 31. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 32. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 33. EUROPE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 34. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 35. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 36. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 37. GERMANY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 38. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 39. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 40. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 41. U.K THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 42. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 43. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 44. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 45. FRANCE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 46. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 47. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 48. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 49. ITALY THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 50. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 51. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 52. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 53. SPAIN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 54. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 55. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 56. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 57. ROE THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 58. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 59. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 60. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 61. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 62. ASIA PACIFC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 63. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 64. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 65. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 66. CHINA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 67. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 68. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 69. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 70. INDIA THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 71. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 72. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 73. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 74. JAPAN THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 75. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 76. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 77. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 78. REST OF APAC THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 79. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISEASE TYPE, 2020-2026 (USD BILLION)
TABLE 80. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DRUG TYPE, 2020-2026 (USD BILLION)
TABLE 81. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2020-2026 (USD BILLION)
TABLE 82. REST OF WORLD THYROID GLAND DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2020-2026 (USD BILLION)
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. ABBVIE INC: FINANCIALS
TABLE 87. ABBVIE INC: PRODUCTS & SERVICES
TABLE 88. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 89. ALLERGAN PLC: FINANCIALS
TABLE 90. ALLERGAN PLC: PRODUCTS & SERVICES
TABLE 91. ALLERGAN PLC: RECENT DEVELOPMENTS
TABLE 92. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 94. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 95. LANNETT COMPANY, INC: FINANCIALS
TABLE 96. LANNETT COMPANY, INC: PRODUCTS & SERVICES
TABLE 97. LANNETT COMPANY, INC: RECENT DEVELOPMENTS
TABLE 98. MERCK & CO. INC: FINANCIALS
TABLE 99. MERCK & CO. INC: PRODUCTS & SERVICES
TABLE 100. MERCK & CO. INC: RECENT DEVELOPMENTS
TABLE 101. MYLAN N.V: FINANCIALS
TABLE 102. MYLAN N.V: PRODUCTS & SERVICES
TABLE 103. MYLAN N.V: RECENT DEVELOPMENTS
TABLE 104. NOVARTIS AG: FINANCIALS
TABLE 105. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 106. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 107. PFIZER INC: FINANCIALS
TABLE 108. PFIZER INC: PRODUCTS & SERVICES
TABLE 109. PFIZER INC: RECENT DEVELOPMENTS
TABLE 110. RLC LABS, INC: FINANCIALS
TABLE 111. RLC LABS, INC: PRODUCTS & SERVICES
TABLE 112. RLC LABS, INC: RECENT DEVELOPMENTS

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

IHR Insights社の医療分野での最新刊レポート


よくあるご質問


IHR Insights社はどのような調査会社ですか?


IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。 主な調査分野 ◇ICT ◇化学品、材料、... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15 10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る